# Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

> **NCT02189174** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** CLR457

## Key facts

- **NCT ID:** NCT02189174
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08-07
- **Primary completion:** 2015-11-12
- **Final completion:** 2015-11-12
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Novartis decided to terminate the study considering safety and tolerability concerns and limited clinical activity with CLR457 study drug administered once daily (qd).
- **Last updated:** 2021-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02189174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02189174, "Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02189174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*